In this engaging discussion, Robert Wharton, a pulmonary fellow at Johns Hopkins, and Nicole Ng, an Assistant Professor at Mount Sinai specializing in interstitial lung disease, delve into the complexities of treating Idiopathic Pulmonary Fibrosis (IPF). They analyze the landmark INPULSIS trials and the efficacy of Nintedanib, highlighting its impact on lung function. The duo discusses challenges like participant selection in clinical trials, adverse effects of the drug, and the importance of personalized treatment strategies to improve patient outcomes.
